Sign In
Buy DMAC
$7.49
-0.180 (-2.35%)
At Close: Jul 13, 2026
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
09:00am, Tuesday, 23'rd Jun 2026
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia, fetal growth restriction a
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
08:30am, Tuesday, 23'rd Jun 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia, fetal growth restriction and acute is
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
08:30am, Tuesday, 16'th Jun 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, today announced that it has received a written response from the U.S. Food and Dru
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
04:30pm, Wednesday, 27'th May 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
08:30am, Wednesday, 20'th May 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke, preeclampsia and
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
04:15pm, Tuesday, 12'th May 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a
DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call Transcript
03:11pm, Thursday, 07'th May 2026
DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call Transcript
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
04:30pm, Wednesday, 06'th May 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restrict
DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
08:25am, Thursday, 30'th Apr 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a
DiaMedica Therapeutics Highlights DM199 Preeclampsia Data, Stroke Interim Catalyst at RedChip Conference
01:05am, Saturday, 18'th Apr 2026
DiaMedica Therapeutics (NASDAQ: DMAC) President and CEO Rick Pauls outlined the company's development programs for its lead candidate, DM199, during a presentation at the RedChip Biotech Investor Conf
DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript
10:52am, Tuesday, 31'st Mar 2026
DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
04:45pm, Monday, 30'th Mar 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restrict
Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings
04:56am, Monday, 30'th Mar 2026
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) will release earnings for its fourth quarter after the closing bell on Monday, March 30.
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Average Rating of “Moderate Buy” by Brokerages
04:42am, Sunday, 29'th Mar 2026
Shares of DiaMedica Therapeutics, Inc. (NASDAQ: DMAC - Get Free Report) have received a consensus rating of "Moderate Buy" from the six brokerages that are covering the firm, MarketBeat Ratings report
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
08:25am, Monday, 23'rd Mar 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a
